HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ursodeoxycholyl lysophosphatidylethanolamide

has both anti-inflammatory and anti-apoptotic activities; structure in first source

Networked: 9 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Stremmel, Wolfgang: 8 articles (11/2019 - 02/2012)
2.	Chamulitrat, Walee: 7 articles (01/2017 - 02/2012)
3.	Pathil, Anita: 7 articles (01/2017 - 02/2012)
4.	Wang, Jiliang: 2 articles (01/2020 - 04/2015)
5.	Gan-Schreier, Hongying: 2 articles (01/2017 - 11/2013)
6.	Liebisch, Gerhard: 2 articles (09/2015 - 11/2013)
7.	Schmitz, Gerd: 2 articles (09/2015 - 11/2013)
8.	Xu, Weihong: 2 articles (02/2015 - 11/2013)
9.	Warth, Arne: 2 articles (05/2012 - 02/2012)
10.	Chen, Ke: 1 article (01/2020)

Related Diseases

1.	Non-alcoholic Fatty Liver Disease 05/01/2012 - "Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease." 09/01/2015 - "Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD." 11/01/2013 - "Ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE) is a hepatoprotectant in inhibiting apoptosis, inflammation, and hyperlipidemia in mouse models of nonalcoholic steatohepatitis (NASH). " 05/01/2012 - "As an experimental approach for treatment of NAFLD, we synthesized the bile acid-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE). " 09/01/2015 - "The bile acid phospholipid conjugate Ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE) is a novel anti-inflammatory agent with hepatoprotective effects in murine high-fat-diet (HFD)-induced NAFLD. "
2.	Inflammation (Inflammations) 04/01/2015 - "We have designed a cytoprotective agent, ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE), which promotes the survival of cultured hepatocellular cell lines and inhibits apoptosis and inflammation in the in vivo models of liver injury. " 05/01/2012 - "Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease." 11/01/2013 - "Ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE) is a hepatoprotectant in inhibiting apoptosis, inflammation, and hyperlipidemia in mouse models of nonalcoholic steatohepatitis (NASH). "
3.	Massive Hepatic Necrosis 01/01/2017 - "Ursodeoxycholyl Lysophosphatidylethanolamide Protects Against CD95/FAS-Induced Fulminant Hepatitis." 02/01/2012 - "Ursodeoxycholyl lysophosphatidylethanolamide inhibited TNFα/CHX-induced apoptosis in HepG2 cells in a dose-dependent manner and markedly ameliorated Gal/LPS-mediated fulminant hepatitis in mice. " 01/01/2017 - "We designed a bile-acid phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE with LPE containing oleate at the sn-1) as a hepatoprotectant that was shown to protect against fulminant hepatitis induced by endotoxin. "
4.	Reperfusion Injury 04/01/2015 - "Ursodeoxycholyl lysophosphatidylethanolamide protects against hepatic ischemia and reperfusion injury in mice." 01/01/2020 - "Ursodeoxycholyl lysophosphatidylethanolamide protects against hepatic ischemia/reperfusion injury via phospholipid metabolism-mediated mitochondrial quality control."
5.	Ischemia 02/01/2015 - "Ursodeoxycholyl lysophosphatidylethanolamide may thus be used as an agent to prevent hepatic ischemia reperfusion. " 04/01/2015 - "Ursodeoxycholyl lysophosphatidylethanolamide protects against hepatic ischemia and reperfusion injury in mice."

Related Drugs and Biologics

1.	Phospholipids (Phosphatides)
2.	Bile Acids and Salts (Bile Acids)
3.	CASP8 and FADD-Like Apoptosis Regulating Protein (FLIP-S)
4.	Oleic Acid (Oleate)
5.	Proteins (Proteins, Gene)
6.	Lipids
7.	Glycochenodeoxycholic Acid (Glycochenodeoxycholate)
8.	Endotoxins
9.	Anti-Inflammatory Agents (Anti-Inflammatories)
10.	Baculoviral IAP Repeat-Containing 3 Protein